

GeNeuro announces participation at upcoming investor events

Geneva, Switzerland, 6 September 2016 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), today announced that management will participate in the upcoming investor events outlined below:

- **NewsMakers in the Biotech Industry 2016**, September 9 2016 - New York, USA
- **Rodman & Renshaw 18th Annual Healthcare Conference**, September 12 & 13, 2016 - New York, USA
- **16th Sachs Annual Biotech in Europe Forum**, September 27 and 28, 2016 - Basel, Switzerland
- **Mid Cap Event**, October 5 & 6, 2016 - Paris, France

Next financial communication

Financial results for the first six months of 2016 and business update: *September 29, 2016 after market close*

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA; a new frontier pioneered by GeNeuro since 2006 and based on research by Institut Mérieux and INSERM.

GeNeuro's first product, GNbAC1, is the first drug candidate in clinical studies directly targeting a potential cause of MS. It is designed to neutralize MSRV-Env, a protein linked to the inflammatory and neurodegenerative components of the disease and could represent a paradigm shift in the options for treating multiple sclerosis. GNbAC1 is being developed under a collaboration agreement for the rights ex US and Japan with Servier that could generate, excluding royalties, over €360 million in revenue for GeNeuro, €37.5 million of which is allocated to financing the ongoing Phase IIb clinical trial in this disease.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com.

Contacts

GeNeuro	NewCap (France)	Halsin Partners	LifeSci Advisors
Jesús Martin-Garcia	Julien Perez (investors)	Mike Sinclair (media)	Chris Maggos (investors)
Chairman and CEO	+33 1 44 71 98 52	+44 20 7318 2955	+1 646 597 6970
+41 22 794 50 85	Nicolas Merigeau (media)	msinclair@halsin.com	+41 79 367 6254
investors@geneuro.com	+33 1 44 71 94 98		chris@lifesciadvisors.com
	geneuro@newcap.eu		